We've updated our Privacy Policy to make it clearer how we use your personal data.

We use cookies to provide you with a better experience, read our Cookie Policy

Advertisement

“Silencing” nsp14 Protein To Weaken SARS-CoV-2

News   Mar 25, 2021 | Original story from ITQB NOVA

 
“Silencing” nsp14 Protein To Weaken SARS-CoV-2

Interfering with nsp14 binding and with the nsp10-nsp14 protein complex is the aim of the most recent ITQB NOVA research in COVID-19. Credit: ITQB NOVA

 
 
Advertisement
 

RELATED ARTICLES

UK Government-Funded COVID-19 Vaccine Phase 1/2 Trials Report Positive Data

News

A new COVID-19 vaccine candidate – VLA2001 – developed by Valneva has shown positive results in a UK Government-funded Phase I/II clinical trial, according to a press release.

READ MORE

Molecular Devices Opens Organoid Innovation Center

News

Molecular Devices, LLC., has opened an Organoid Innovation Center at the company’s global headquarters. The center expands beyond imaging to demonstrate an end-to-end solution that addresses challenges associated with every step in the sample prep-to-report pipeline for assays performed on complex 3D biological models.

READ MORE

New Classification System Developed for MS-Like Syndrome

News

Researchers have developed a classification scheme for neuromyelitis optica spectrum disorder, a rare autoimmune disease that until recently was thought to be a type of multiple sclerosis (MS).

READ MORE

 

Like what you just read? You can find similar content on the communities below.

Immunology & Microbiology

To personalize the content you see on Technology Networks homepage, Log In or Subscribe for Free

LOGIN SUBSCRIBE FOR FREE